Past studies have shown that the inositol polyphosphate 5-phosphatase, phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PIB5PA), is commonly downregulated or lost in melanomas, which contributes to elevated activation of phosphatidylinositol 3-kinase (PI3K)/Akt in melanoma cells. In this report, we provide evidence that PIB5PA deficiency plays a role in resistance of melanoma cells to RAF/mitogen-activated protein kinase kinase (MEK) inhibitors. Ectopic expression of PIB5PA enhanced apoptosis induced by the RAF inhibitor PLX4720 in BRAF V600E and by the MEK inhibitor U0126 in both BRAF V600E and wild-type BRAF melanoma cells. This was due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of overexpression of PIB5PA on apoptosis induced by PLX4720 or U0126. While overexpression of PIB5PA triggered activation of Bad and down-regulation of Mcl-1, knockdown of Bad or overexpression of Mcl-1 recapitulated, at least in part, the effect of myr-Akt, suggesting that regulation of Bad and Mcl-1 is involved in PIB5PA-mediated sensitization of melanoma cells to the inhibitors. The role of PIB5PA deficiency in BRAF inhibitor resistance was confirmed by knockdown of PIB5PA, which led to increased growth of BRAF V600E melanoma cells selected for resistance to PLX4720. Consistent with its role in vitro, overexpression of PIB5PA and the MEK inhibitor selumetinib cooperatively inhibited melanoma tumor growth in a xenograft model. Taken together, these results identify loss of PIB5PA as a novel resistance mechanism of melanoma to RAF/MEK inhibitors and suggest that restoration of PIB5PA may be a useful strategy to improve the therapeutic efficacy of the inhibitors in the treatment of melanoma.
Introduction
Aberrant activation of survival signaling pathways causes uncontrolled proliferation and resistance to apoptosis and plays an important role in cancer development, progression, and resistance to treatment [1, 2] . In melanoma, activation of the mitogen-activated protein kinase pathway stems primarily from activating mutations of BRAF with the most common mutation being a glutamic acid for valine substitution at position 600 (BRAF V600E ) [3, 4] . Targeting mutant BRAF using small molecule inhibitors such as vemurafenib and dabrafenib has achieved unprecedented responses in metastatic melanoma patients [5] [6] [7] . However, complete remission is rare and a proportion of mutant BRAF melanomas are less responsive to the inhibitors, indicative of inherent resistance [5, [8] [9] [10] . Moreover, durations of responses are commonly limited with most patients relapsing within 1 year, indicative of development of acquired drug resistance [5, [8] [9] [10] .
Multiple mechanisms have been shown to contribute to resistance of mutant BRAF melanomas to BRAF inhibitors [5, [8] [9] [10] . These include those leading to insufficient inhibition of RAF/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling and those promoting melanoma cell survival and proliferation alternative to the RAF/MEK/ERK pathway, such as increased activation of the phosphatidylinositol 3-kinase (PI3K)/Akt or nuclear factor kappalight-chain-enhancer of activated B cells (NF-κB) pathway [11] [12] [13] [14] [15] [16] [17] [18] [19] . Indeed, combinations of RAF inhibitors and inhibitors of MEK such as trametinib to further inhibit MEK/ERK signaling have yielded promising results in clinical trials [20] [21] [22] . Co-targeting the PI3K/Akt and RAF/MEK/ERK pathways is also being evaluated in early clinical studies [17, 23] .
PI3K signaling is initiated with engagement of extracellular growth factors to receptor tyrosine kinases. This results in recruitment of PI3K to plasma membrane-anchored receptors where it is activated leading to increases in the production of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P 3 ), which, in turn, bind to and activate multiple downstream effectors [24] [25] [26] . Among them is Akt that is activated by two phosphorylation events at Thr 308 and Ser 473 involving phosphoinositide-dependent kinases 1 and 2, respectively [27, 28] . While phosphorylation at the Thr 308 partially activates Akt, its full activation requires phosphorylation at Ser 473 [27] [28] [29] [30] . The intracellular levels of PI(3,4,5)P 3 are negatively regulated through dephosphorylation by two classes of inositol polyphosphate phosphatases [31, 32] . The 3-phosphatase, phosphate and tensin homolog deleted on chromosome 10 (PTEN), dephosphorylates the 3-position of PI(3,4,5)P 3 to generate phosphatidylinositol 4,5-bisphosphate [33, 34] , whereas 5-phosphatases, such as Src homology 2-containing inositol 5-phosphatase, Src homology 2-containing inositol 5-phosphatase 2, and phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PIB5PA)/proline-rich inositol polyphosphate phosphatase, dephosphorylate the 5-position to produce phosphatidylinositol 3,4-bisphosphate [33] . The latter is, in turn, subjected to dephosphorylation by inositol polyphosphate 4-phosphatase type I (INPP4A) and type II (INPP4B) at the 4-position to terminate PI3K signaling [34] [35] [36] . Whereas PTEN is a well-established tumor suppressor [32, 37] , we have recently shown that PIB5PA that is also commonly downregulated or lost similarly plays an important role in negative regulation of PI3K/ Akt and has a tumor-suppressive role in melanoma [38] .
In this study, we have examined the potential effect of PIB5PA deficiency on sensitivity of melanoma cells to BRAF and MEK inhibitors. We report here that introduction of exogenous PIB5PA sensitizes melanoma cells to apoptosis induced by inhibition of RAF/MEK/ERK signaling in vitro and in vivo and that this is due to inhibition of PI3K/ Akt signaling. In addition, we demonstrate that PIB5PA deficiency contributes to growth of BRAF V600E melanoma cells selected for resistance to PLX4720. These results suggest that restoration of PIB5PA expression may be a useful strategy to improve the therapeutic efficacy of RAF and MEK inhibitors in the treatment of melanoma.
Materials and Methods
Cell Culture, Reagents, and Antibodies
The human melanoma cell lines, ME1007, Mel-FH, MM200, Mel-RMu, Mel-CV, and IgR3, which have been previously described, were cultured in Dulbecco's modified Eagle's medium containing 5% fetal calf serum [18] . ME1007 and Mel-FH harbor wild-type BRAF, whereas MM200, Mel-RMu, Mel-CV, and IgR3 carry BRAF V600E . PLX4720-resistant Mel-RMu.S and Mel-CV.S sublines were generated and maintained as reported before [18] . None of the cell lines harbors activating mutations in PTEN, PIK3CA, BRAF, NRAS, KIT, and EGFR (data not shown). All of them carry wild-type PIB5PA as shown by analysis of all the 13 exons (including the intron/exon boundaries) of the gene encoding PIB5PA, INPP5J (data not shown). The MEK inhibitor U0126 was purchased from Promega (San Luis Obispo, CA). The MEK inhibitor selumetinib (AZD6244; ARRY-142886) and the BRAF inhibitor PLX4720 were purchased from Selleck (Houston, TX). These inhibitors were dissolved in DMSO (SigmaAldrich, Shanghai, China). The rabbit polyclonal antibody against caspase-3 was from Stressgen (Farmingdale, NY). Antibodies against PIB5PA, Mcl-1, pSer136-Bad, p-ERK1/2, Bcl-2, Bcl-X L , and Smac/ DIABLO were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against pSer473-Akt, Akt, ERK1/2, Bad, and Puma were from Cell Signaling Technology (Beverly, MA). Antibodies against poly (ADP-ribose) polymerase (PARP) and cytochrome c were from BD Pharmingen (North Ryde, NSW, Australia). Antibodies against Bim and Noxa were from IMGENEX (Stepney, SA, Australia). The mouse antibody against COX IV was from Clontech (Mountain View, CA). The mouse monoclonal antibody against β-actin was from Abcam (Cambridge, MA). The antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was from Ambion (Carlsbad, CA).
Establishment of Melanoma Cell Lines Carrying an Inducible PIB5PA Expression System
A lentivirus-based inducible gene expression system described previously was used to express PIB5PA conditionally in melanoma cells [39] . Briefly, the system involves co-infection of two lentiviral particles: one encoding the inducible transcriptional activator Gal4 1-147 ER T2 VP16 (GEV16) cloned into pFU-GEV16-PGK-Hygro containing a hygromycin B resistance gene, and another, PIB5PA cDNA cloned into pF-5xUAS-SV40-puro containing a puromycin resistance gene. Dual antibiotic selection was applied deriving a cell population carrying both GEV16 and PIB5PA. Application of low nM concentrations of 4-hydroxytestosterone (4-OHT) drives the expression of PIB5PA. Two melanoma cell lines (ME1007 and Mel-FH) were used to establish sublines carrying inducible exogenous PIB5PA (ME1007.PIB5PA and Mel-FH.PIB5PA).
Melanoma Xenograft Mouse Model
Viable ME1007.PIB5PA cells (1 × 10 7 cells per mouse) with or without pretreatment with 4-OHT (10 nM) for 36 hours were injected subcutaneously into right posterior flanks of nu/nu mice (Shanghai SLAC Laboratory, Shanghai, China). Mice were then randomly assigned into four groups (n = 6 for each group) that were, respectively, treated with DMSO, selumetinib (25 mg/kg), 4-OHT (10 nM/g), and 4-OHT plus selumetinib through intraperitoneal injection every 3 days. Tumor volumes were monitored using an electronic caliper twice per week and calculated using the following formula: tumor volume (mm 
Western Blot Analysis
Cells were harvested by trypsinization and washed with phosphatebuffered saline, then disrupted on ice for 30 minutes in NP-40 lysis buffer and cleared by centrifugation as previously described [18] . Equal amounts of protein (30 μg) in cell lysate were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to membranes, immunoblotted with specific primary and secondary antibodies, and detected by Immun-Star HRP Chemiluminescent Kit. The images were captured and the intensity of the bands was quantitated using the Bio-Rad VersaDoc image system (Bio-Rad, Gladesville, NSW, Australia).
CellTiter-Glo Assays
The CellTiter-Glo Assay was performed with the CellTiter-Glo Luminescent Cell Viability Assay kit according to the manufacturer's instructions (Promega). Luminescence was recorded by Synergy 2 multi-detection microplate reader (Bio-Tek, Winooski, VT).
Apoptosis
Quantitation of apoptotic cells was carried out by measurement of sub-G 1 DNA content using propidium iodide in a flow cytometer as described elsewhere [18] . In brief, cells were seeded at 1 × 10 5 /well onto 24-well culture plates and allowed to grow for 24 hours followed by the desired treatment. Cells were harvested with propidium iodide buffer, transferred to fluorescence-activated cell sorting (FACS) tubes, and incubated overnight at 4°C in the dark before analysis.
BrdU Proliferation Assays
5-Bromo-2′-deoxyuridine (BrdU) cell proliferation assays were carried out using an assay kit (Cell Signaling Technology) as per the manufacturer's instructions. Briefly, cells were seeded at 5 × 10 3 /well in 96-well plates overnight before treatment as desired. BrdU (10 mM) was added and cells were incubated for 4 hours before BrdU assays were carried out. Absorbance was read at 450 nm using a Synergy 2 multidetection microplate reader (Bio-Tek).
Clonogenic Assays
Cells were seeded at 2000/well onto six-well culture plates and allowed to grow for 24 hours followed by the desired treatment. Cells were then allowed to grow for another 12 days before fixation with methanol and staining with crystal violet.
Preparation of Mitochondrial and Cytosolic Fractions
The mitochondrial and cytosolic fractions were prepared by using the Qproteome Mitochondrion Isolation Kit (Qiagen, Doncaster, Australia) according to the manufacturer's instruction. In brief, after trypsinization, cells were washed with phosphate-buffered saline followed with 0.9% sodium chloride solution. Cell pellets were resuspended in ice-cold lysis buffer and incubated for 10 minutes at 4°C on an end-over-end shaker. Cell lysates were then spun at 1000 g for 10 minutes at 4°C and resulting supernatants were collected as cytosolic fractions.
Plasmid Vectors and Transfection
The pCGN-PIB5PA-human influenza hemagglutinin (HA) construct was a generous gift from Christina A. Mitchell (Monash University, Victoria, Australia). The pcDNA-myr-HA-Akt construct was purchased from Addgene (Cambridge, MA; Plasmid 9017). The pcDNA-Mcl-1-flag construct was provided by Professor Mian Wu from the University of Science and Technology of China. Cells were transfected with 2 μg of plasmid as well as the empty vector in Opti-MEM medium (Invitrogen, Shanghai, China) with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol.
Small Interfering RNA
Transfection of small interfering RNA (siRNA) pools was carried out as described previously [18] . Melanoma cells were seeded at 1 × 10 5 cells per well in 24-well plates and allowed to reach 50% confluence on the day of transfection. The siRNA constructs for Bad and PIB5PA were obtained as the siGENOMESMARTpool reagents (Dharmacon, Lafayette, CO), the siGENOMESMARTpoolBad (M-003870-02-0010) and the siGENOME SMARTpool PIB5PA (M-009108-01-0010). The non-targeting siRNA control, SiConTRol-Non-targeting siRNA pool (D-001206-13-20), was also obtained from Dharmacon. Cells were transfected with 50 nM/l siRNA in Opti-MEM medium (Invitrogen) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's transfection protocol.
Statistical Analysis
The significance of differences between experimental data was determined with the two-tailed Student's t test for unpaired observations using SPSS 11.0 (SPSS, Chicago, IL) software. A P value < .05 was considered statistically significant.
Results
Wild-type BRAF Melanoma Cells Overexpressing PIB5PA Are More Susceptible to Apoptosis Induced by the MEK Inhibitor U0126
To study the impact of PIB5PA on sensitivity of melanoma cells to inhibition of the MEK/ERK pathway, we took advantage of two melanoma sublines (ME1007.PIB5PA and Mel-FH.PIB5PA) conditionally expressing PIB5PA in response to 4-OHT that were established by transduction of a lentivirus-based inducible gene expression system as described previously ( Figure 1A ) [38] . These cell lines and their corresponding parental counterparts (ME1007 and Mel-FH, respectively) harbored wild-type BRAF. As reported before, 4-OHT inhibited viability of ME1007.PIB5PA and Mel-FH.PIB5PA cells as measured by CellTiter-Glo assays but did not impinge on survival of ME1007 and Mel-FH cells ( Figure 1B ) [38] . However, the MEK inhibitor U0126 triggered moderate inhibition of cell viability in both ME1007.PIB5PA and Mel-FH.PIB5PA and ME1007 and Mel-FH cells ( Figure 1B ). Although the combination of U0126 and 4-OHT did not increase the inhibitory effect on cell survival in ME1007 and Mel-FH cells in comparison with treatment with U0126 alone, it markedly enhanced the inhibitory effect on survival of ME1007.PIB5-PA and Mel-FH.PIB5PA cells (P < .01, two-tailed Student's t test). The enhanced effect of the combination of U0126 and 4-OHT on viability of these cells was also reflected by reduced clonogenicity ( Figure 1C ).
We examined if induction of apoptosis was involved in increased inhibition of cell viability by the combination of U0126 and 4-OHT. As shown in Figure 1D , U0126 induced moderate levels of apoptosis in ME1007.PIB5PA and Mel-FH.PIB5PA and ME1007 and Mel-FH Figure 1E ). However, it did not increase apoptosis in ME1007 and Mel-FH cells compared with treatment with U0126 alone ( Figure 1D ). The inhibitory effect of U0126 on the MEK/ERK pathway was corroborated by reduced phosphorylation of ERK1/2 ( Figure 1E ) and the inhibitory effect of 4-OHT on PI3K/Akt signaling in ME1007. PIB5PA and Mel-FH.PIB5PA by reduction in phosphorylation of Akt ( Figure 1A ).
Overexpression of PIB5PA Sensitizes BRAFV600E Melanoma Cells to Apoptosis Induced by Either the RAF Inhibitor PLX4720 or the MEK Inhibitor U0126
We next examined whether overexpression of PIB5PA impacts on sensitivity of BRAF V600E melanoma cells to apoptosis induced by the RAF inhibitor PLX4720. To this end, we transiently introduced an HA-tagged PIB5PA construct into IgR3 and MM200, two BRAF V600E melanoma cell lines that were relatively resistant to apoptosis induced by the RAF inhibitor PLX4720 (Figure 2A ). Overexpression of PIB5PA only caused moderate levels of apoptosis (<20% apoptotic cells), consistent with previous findings (Figure 2 , B and C) [38] . However, it sensitized both IgR3 and MM200 cells to PLX4720-induced apoptosis ( Figure 2B ). Similarly, it enhanced sensitivity of the cells to apoptosis induced by the MEK inhibitor U0126 ( Figure 2C ). The inhibitory effects of overexpression of PIB5PA and PLX4720 on activation of Akt and ERK were shown in Figure 2 , A and D, respectively. Taken together, these results indicate that PIB5PA sensitizes melanoma cells to apoptosis induced by inhibition of MEK/ERK signaling.
PIB5PA-mediated Sensitization of Melanoma Cells to RAF and MEK Inhibitors Is due to Its Inhibitory Effect on PI3K/Akt
Because overexpression of PIB5PA inhibited activation of Akt ( Figures 1A and 2A ) [38] , we examined whether this is causative for its effect on sensitivity of melanoma cells to apoptosis induced by inhibition of MEK/ERK signaling. To do so, we introduced an active form of Akt (myr-Akt) into Mel-FH.PIB5PA and ME1007. PIB5PA cells ( Figure 3A ) [40] . As shown in Figure 3B , myr-Akt efficiently reversed 4-OHT-triggered enhancement of apoptosis induced by U0126. Similarly, co-introduction of myr-Akt and PIB5PA into IgR3 and MM200 cells markedly reduced the sensitizing effect of PIB5PA on PLX4720-induced apoptosis (Figure 3, C and D) . These results indicate that the effect of overexpression of PIB5PA on melanoma cell survival is mediated by its inhibitory effect on PI3K/Akt signaling.
Sensitization of Melanoma Cells to Apoptosis Induced by Inhibition of MEK/ERK Signaling Is Inhibitable by Mcl-1
Both PLX4720 and U0126 induce apoptosis of melanoma cells by activation of the mitochondrial apoptotic pathway [41, 42] . Consistent with this, while co-treatment of ME1007.PIB5PA cells with U0126 in the presence of 4-OHT resulted in increased mitochondrial release of cytochrome c and Smac/DIABLO into the cytosol, transient overexpression of PIB5PA similarly caused increases in release of these mitochondrial apoptogenic proteins in IgR3 cells ( Figure 4A ), suggesting that the mitochondrial apoptotic pathway is involved in PIB5PA-mediated sensitization of melanoma cells to apoptosis induced by inhibition of MEK/ERK. Indeed, overexpression of Mcl-1 in ME1007.PIB5PA cells markedly inhibited apoptosis induced by U0126 in the absence or presence of 4-OHT (P < .01, two-tailed Student's t test; Figure 4B ). Consistently, the sensitizing effect of overexpression of PIB5PA on IgR3 cells to PLX4720-induced apoptosis was significantly blocked when exogenous Mcl-1 was co-introduced ( Figure 4C ). These results indicate that the mitochondrial apoptotic pathway is essential for PIB5PA-mediated sensitization of melanoma cells to apoptosis induced by inhibition of MEK/ERK signaling. 
Bad Plays an Important Role in PIB5PA-Mediated Sensitization of Melanoma Cells to Apoptosis Induced by Inhibition of MEK/ERK Signaling
To further study the mechanism by which overexpression of PIB5PA enhances apoptosis induced by inhibition of MEK/ERK signaling, we examined the expression of Bcl-2 family proteins in ME1007.PIB5PA cells with or without exposure to 4-OHT and in IgR3 cells introduced with exogenous PIB5PA in comparison with those transfected with vector-HA. As shown in Figure 5A , overexpression of PIB5PA downregulated Mcl-1 and reduced the levels of phosphorylated Bad. In contrast, the expression levels of Bcl-2, Bcl-X L , Bim, PUMA, and Noxa remained unaltered in PIB5PA-overexpressing cells compared with corresponding control cells. 
Overexpression of PIB5PA in Combination with the MEK Inhibitor Selumetinib Enhances the Inhibitory Effect on Melanoma Growth in a Xenograft Mouse Model
Overexpression of PIB5PA is known to reduce melanoma xenograft growth in immunodeficient mice [38] . The MEK inhibitor selumetinib also inhibits melanoma growth in mouse models [43] . We examined whether the combination of overexpression of PIB5PA and selumetinib further enhance the inhibitory effect in vivo. To this end, tumor growth of ME1007.PIB5PA cells subcutaneously transplanted into nu/nu mice treated with the vehicle control, 4-OHT, selumetinib, or the combination of 4-OHT and selumetinib was examined. Although treatment with 4-OHT and, to a lesser extent, treatment with selumetinib reduced melanoma growth in vivo (Figure 6 , A-C), the combination of both resulted in significantly greater inhibition of tumor growth ( Figure 6, A-C) . This was associated with induction of PIB5PA, suppression of activation of Akt, down-regulation of Mcl-1 and phosphorylated Bad, and activation of caspase-3 as shown by examination of tumors from postmortem animals ( Figure 6D ).
PIB5PA Deficiency Contributes to Growth of BRAF

V600E
Melanoma Cells Selected for Resistance to PLX4720
To obtain more direct evidence that PIB5PA deficiency contributes to resistance of BRAF V600E melanoma cells to BRAF inhibitors, we knocked down PIB5PA in two PLX4720-resistant melanoma sublines (Mel-RMu.S and Mel-CV.S) that were established by prolonged exposure of their parental counterparts (Mel-RMu and Mel-CV, respectively) to the inhibitor [18] . Similar to their parental cells, Mel-RMu.S and Mel-CV.S cells expressed low but detectable levels of PIB5PA ( Figure 7A ). siRNA knockdown of PIB5PA resulted in increased proliferation of Mel-RMu.S and Mel-CV.S cells as shown in BrdU incorporation and clonogenic assays ( Figure 7 , B and C ) and, as expected, reduced sensitivity of Mel-RMu and Mel-CV to PLX4720 ( Figure 7D ). This was associated with increased activation of Akt ( Figure 7A ). These results consolidate the role of PIB5PA in regulating sensitivity of BRAF V600E melanoma cells to BRAF inhibitors.
Discussion
In this report, we present evidence that loss of the 5-phosphatase PIB5PA plays an important role in resistance of melanoma cells to inhibition of the RAF/MEK/ERK pathway. While its expression is commonly reduced or lost in melanoma cells in vitro and in vivo [38] , introduction of exogenous PIB5PA resulted in enhanced induction of apoptosis by the RAF inhibitor PLX4720 in BRAF and wild-type BRAF melanoma cells and enhanced the therapeutic efficacy of the MEK inhibitor selumetinib in a melanoma xenograft mouse model. Moreover, we show that inhibition of PIB5PA enhances growth of BRAF V600E melanoma cells selected for resistance to PLX4720.
Inhibition of RAF/MEK/ERK signaling constrains melanoma cell proliferation and induces apoptosis [4, 7, 10] . However, previous studies have suggested a determining role of sensitivity to induction of apoptosis in long-term responses of melanoma cells to BRAF or MEK inhibitors [18] . Killing of cells occurred at early stages after exposure of sensitive BRAF V600E melanoma cells to PLX4720, but the remaining cells retained low proliferation potential even in the presence of the inhibitor and regained high growth rate after it was withdrawn [18] . This mirrors closely the clinical observation that mutant BRAF melanomas frequently regress in response to BRAF inhibitors but recur within relatively short periods [5] [6] [7] . Overcoming resistance of melanoma cells to apoptosis appears therefore imperative in improving therapeutic efficacy of RAF and MEK inhibitors.
Many mechanisms have been reported to be involved in resistance of melanoma cells to inhibition of the RAF/MEK/ERK pathway [5, [8] [9] [10] . Among them, activation of the PI3K/Akt pathway is of particular importance, in that PI3K/Akt signaling has been shown to cooperate with mutant BRAF in melanomagenesis using in vivo models and that melanoma cells resistant to RAF inhibitors display increased activation of PI3K/Akt [18] . In addition, loss of PTEN that negatively regulates PI3K/Akt confers resistance of melanoma cells to BRAF inhibitors and cooperates with BRAF V600E to induce metastatic melanoma [16] .
We have recently shown that, similar to PTEN, the 5-phosphatase PIB5PA is frequently lost in melanoma cells and has an important role in inhibiting PI3K/Akt signaling and in suppressing melanoma cell proliferation [38] . In this study, loss of PIB5PA was found to similarly play a role in regulating sensitivity of melanoma cells to apoptosis induced by inhibition of the RAF/MEK/ERK pathway, in that introduction of exogenous PIB5PA sensitized melanoma cells to apoptosis induced by the RAF inhibitor PLX4720 in BRAF V600E melanoma cells and by the MEK inhibitor selumetinib in both BRAF V600E and wild-type BRAF melanoma cells. This sensitizing effect was due to the inhibitory effect of PIB5PA on PI3K/Akt signaling, as co-introduction of myr-Akt effectively reduced apoptosis induced by PLX4720 or U0126 in melanoma cells overexpressing PIB5PA.
Activation of the BH3-only protein Bad and down-regulation of Mcl-1 appeared to play important roles in PIB5PA-mediated sensitization of melanoma cells to apoptosis induced by inhibition of RAF/ MEK/ERK signaling, in that introduction of exogenous PIB5PA resulted in reduction in phosphorylation of Bad and decreases in Mcl-1 and that siRNA knockdown of Bad or overexpression of Mcl-1 inhibited the sensitization. Since induction of apoptosis by RAF or MEK inhibitors is known to be mediated by activation of the BH3-only protein Bim and down-regulation of Mcl-1 [41, 42] , it is conceivable that Bad and Bim may cooperatively attenuate anti-apoptotic Bcl-2 family proteins such as Mcl-1. The latter may be further downregulated by RAF or MEK inhibitors in melanoma cells overexpressing PIB5PA. Bad is well documented to be a downstream phosphorylation target of Akt, whereas Mcl-1 is also known to subject to regulation by Akt signaling [44, 45] .
The PI3K/Akt pathway can also negatively regulate the expression of Bim through a FOXO3a-mediated transcriptional mechanism [16] . Consistently, resistance of melanoma cells to RAF inhibitors mediated by loss of PTEN has been shown to be due to suppression of Bim [16] . However, we did not observe any significant change in the Bim expression in melanoma cells overexpressing PIB5PA compared to corresponding controls. The reason for this discrepancy remains unknown, but it is likely to be related to the variations in cell lines used in the different studies. Regardless, our results clearly demonstrated a protective role of loss of PIB5PA in melanoma cells when the RAF/MEK/ERK pathway is inhibited.
An important finding of this study was that the combination of exogenous PIB5PA and the MEK inhibitor selumetinib cooperatively induced apoptosis and inhibited melanoma xenograft growth in vivo. This supports the notion that restoration of the expression of PIB5PA may be a useful strategy to improve the therapeutic efficacy of inhibitors of the RAF/MEK/ERK pathway in the treatment of melanoma. However, since the majority of melanoma cell lines and fresh melanoma isolates expressed low levels of PIB5PA [38] , it remains unknown whether sensitivity of melanoma to RAF and MEK inhibitors correlates in general with PIB5PA expression levels. Regardless, our results showing that knockdown of PIB5PA promoted survival and growth of BRAF V600E melanoma cells selected for resistance to PLX4720 provided direct evidence that loss of PIB5PA plays a role in resistance of melanoma cells to inhibition of the RAF/MEK/ ERK pathway. Studies using melanoma tissue samples from patients with different responses to RAF or MEK inhibitors are warranted to further clarify the role of loss of PIB5PA in resistance of melanoma to the inhibitors. There is a significant difference in fold change of WRN expression in the CRCs compared to normal mucosa by stage (P = .0498); however, after all-pairwise post-hoc comparisons, there was not enough power to detect differences among the stages. The highest median expression is seen in stage II CRC. Higher expression levels of WRN in stage II compared to lower expression levels of WRN in the other tumor stages (compared to matched normal mucosa) can be appreciated. However, no statistical significance is seen in the expression of BLM (P = .2193), RECQL4 (P = .4077), RECQL (P = .5992), or RECQL5 (P = .3889) in the CRCs compared to matched normal tissue in any of the stages. (B) RECQ helicase IHC. On the basis of Allred scores, there is no statistically significant difference in expression of the RECQ helicases in CRCs across stages, WRN (P = .5709), BLM (P = .3644), RECQL4 (P = .5451), RECQL (P = .1922), or RECQL5 (P = .5604).
